Exelixis Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Exelixis Inc 公司

Exelixis, Inc. 是一家肿瘤学公司。该公司已生产了四种上市药品，其中两种是其旗舰分子卡博替尼的配方。该公司还在推进和发展其产品线组合，包括其主要研究资产 zanzalintinib。卡博替尼是多种酪氨酸激酶的抑制剂，包括 MET、AXL、VEGF 受体和 RET，还被批准作为 CABOMETYX 片剂用于晚期肾细胞癌、先前治疗过的肝细胞癌和先前治疗过的放射性碘难治性分化性甲状腺癌，以及作为 COMETRIQ 胶囊用于进行性转移性髓样甲状腺癌。该公司的另外两种产品是 COTELLIC，一种 MEK 抑制剂，被批准作为多种联合方案的一部分用于治疗特定形式的晚期黑色素瘤，以及 MINNEBRO，一种口服、非甾体、选择性盐皮质激素受体阻滞剂，在日本被批准用于治疗高血压。

Exelixis Inc简介



公司代码EXEL

公司名称Exelixis Inc

上市日期Apr 11, 2000

CEODr. Michael M. Morrissey, Ph.D.

员工数量1147

证券类型Ordinary Share

年结日Apr 11

公司地址1851 Harbor Bay Parkway

城市ALAMEDA

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编94502

电话16508377000

网址https://www.exelixis.com/

公司代码EXEL

上市日期Apr 11, 2000

CEODr. Michael M. Morrissey, Ph.D.

Exelixis Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Michael M. Morrissey, Ph.D.

President, Chief Executive Officer, Director

2.27M

-4.42%

Dr. Stelios B. Papadopoulos, Ph.D.

Independent Chairman of the Board, Co-Founder

1.27M

+0.78%

Mr. Jeffrey J. Hessekiel, J.D.

Executive Vice President, General Counsel

410.70K

-12.57%

Dr. Dana T. Aftab, Ph.D.

Executive Vice President - Research and Development

359.32K

-8.22%

Mr. Jack L. Wyszomierski

Independent Director

340.04K

-2.17%

Mr. Patrick Joseph Haley

Executive Vice President - Commercial

258.52K

-25.63%

Dr. George H. Poste, Ph.D.

Independent Director

159.99K

+6.53%

Dr. Maria C. Freire, Ph.D.

Independent Director

81.98K

+13.60%

Ms. Julie Anne Smith

Independent Director

10.57K

+1285.98%

Mr. Robert Lee (Bob) Oliver, Jr.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Michael M. Morrissey, Ph.D.

President, Chief Executive Officer, Director

2.27M

-4.42%

Dr. Stelios B. Papadopoulos, Ph.D.

Independent Chairman of the Board, Co-Founder

1.27M

+0.78%

Mr. Jeffrey J. Hessekiel, J.D.

Executive Vice President, General Counsel

410.70K

-12.57%

Dr. Dana T. Aftab, Ph.D.

Executive Vice President - Research and Development

359.32K

-8.22%

Mr. Jack L. Wyszomierski

Independent Director

340.04K

-2.17%

Mr. Patrick Joseph Haley

Executive Vice President - Commercial

258.52K

-25.63%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

CABOMETYX

517.89M

91.14%

License revenues

49.30M

8.68%

COMETRIQ

2.12M

0.37%

Collaboration services revenues

-1.05M

-0.19%

地区USD

名称

营收

占比

U.S

524.77M

92.35%

Europe

37.03M

6.52%

Japan

6.46M

1.14%

业务

地区

业务USD

名称

营收

占比

CABOMETYX

517.89M

91.14%

License revenues

49.30M

8.68%

COMETRIQ

2.12M

0.37%

Collaboration services revenues

-1.05M

-0.19%

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

9.45%

Farallon Capital Management, L.L.C.

5.96%

Renaissance Technologies LLC

5.88%

State Street Investment Management (US)

4.23%

其他

64.31%

持股股东

占比

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

9.45%

Farallon Capital Management, L.L.C.

5.96%

Renaissance Technologies LLC

5.88%

State Street Investment Management (US)

4.23%

其他

64.31%

股东类型

持股股东

占比

Investment Advisor

44.85%

Investment Advisor/Hedge Fund

28.53%

Hedge Fund

15.52%

Research Firm

2.90%

Pension Fund

2.72%

Individual Investor

2.25%

Sovereign Wealth Fund

1.25%

Bank and Trust

0.58%

Family Office

0.19%

其他

1.22%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1092

260.88M

96.91%

-7.90M

2025Q2

1066

261.07M

96.97%

-18.39M

2025Q1

1059

268.29M

98.20%

-10.58M

2024Q4

992

262.76M

93.66%

-11.36M

2024Q3

924

259.58M

90.96%

-10.18M

2024Q2

908

255.61M

87.75%

-22.29M

2024Q1

905

264.69M

87.26%

-20.82M

2023Q4

882

270.85M

87.07%

-16.64M

2023Q3

847

278.02M

87.32%

-18.15M

2023Q2

833

285.95M

87.85%

-21.34M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

27.41M

10.18%

-1.20M

-4.20%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

25.44M

9.45%

-1.05M

-3.97%

Jun 30, 2025

Farallon Capital Management, L.L.C.

16.04M

5.96%

-2.60M

-13.95%

Jun 30, 2025

Renaissance Technologies LLC

15.82M

5.88%

+995.50K

+6.72%

Jun 30, 2025

State Street Investment Management (US)

11.38M

4.23%

-404.95K

-3.43%

Jun 30, 2025

Fuller & Thaler Asset Management Inc.

8.78M

3.26%

+980.50K

+12.58%

Jun 30, 2025

LSV Asset Management

7.82M

2.9%

-340.89K

-4.18%

Jun 30, 2025

AQR Capital Management, LLC

7.61M

2.83%

+712.19K

+10.33%

Jun 30, 2025

Geode Capital Management, L.L.C.

7.45M

2.77%

+28.29K

+0.38%

Jun 30, 2025

Arrowstreet Capital, Limited Partnership

5.26M

1.95%

+1.58M

+42.93%

Jun 30, 2025

持股ETF



更新时间: 10月6日周一

机构名称

占比

iShares Genomics Immunology and Healthcare ETF

3.48%

Invesco Dorsey Wright Healthcare Momentum ETF

3.09%

Tema Oncology ETF

2.99%

First Trust NYSE Arca Biotechnology Index Fund

2.7%

Invesco Biotechnology & Genome ETF

2.24%

SPDR S&P Biotech ETF

2.1%

First Trust NASDAQ Pharmaceuticals ETF

1.92%

Inspire Faithward Mid Cap Momentum ETF

1.84%

AAM Sawgrass US Large Cap Quality Growth ETF

1.83%

First Trust Health Care Alphadex Fund

1.82%

iShares Genomics Immunology and Healthcare ETF

占比3.48%

Invesco Dorsey Wright Healthcare Momentum ETF

占比3.09%

Tema Oncology ETF

占比2.99%

First Trust NYSE Arca Biotechnology Index Fund

占比2.7%

Invesco Biotechnology & Genome ETF

占比2.24%

SPDR S&P Biotech ETF

占比2.1%

First Trust NASDAQ Pharmaceuticals ETF

占比1.92%

Inspire Faithward Mid Cap Momentum ETF

占比1.84%

AAM Sawgrass US Large Cap Quality Growth ETF

占比1.83%

First Trust Health Care Alphadex Fund

占比1.82%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据